In vitro and ex vivo anti-myeloma effects of nanocomposite As
Humans
Albumins
/ metabolism
Apoptosis
Caspases
/ metabolism
Cell Line, Tumor
Cyclin B1
/ metabolism
Folic Acid
/ pharmacology
Histones
/ pharmacology
Lenalidomide
/ pharmacology
Melphalan
/ pharmacology
Multiple Myeloma
/ drug therapy
Nanocomposites
TOR Serine-Threonine Kinases
/ metabolism
Tumor Microenvironment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 10 2022
26 10 2022
Historique:
received:
03
08
2022
accepted:
18
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Nanoparticles in medicine can integrate actively targeted imaging agents and drug delivery vehicles, and combining multiple types of therapeutics in a single particle has numerous advantages, especially in multiple myeloma. MM is an incurable hematological disorder characterized by clonal proliferation of plasma cells in the bone marrow. In this study, we evaluated the anti-myeloma activity of 3 nanocomposites (3NPs): As
Identifiants
pubmed: 36289430
doi: 10.1038/s41598-022-22672-5
pii: 10.1038/s41598-022-22672-5
pmc: PMC9606304
doi:
Substances chimiques
Albumins
0
Caspases
EC 3.4.22.-
Cyclin B1
0
Folic Acid
935E97BOY8
Histones
0
Lenalidomide
F0P408N6V4
Melphalan
Q41OR9510P
TOR Serine-Threonine Kinases
EC 2.7.11.1
zinc sulfide
KPS085631O
ferric oxide
1K09F3G675
tetraarsenic tetrasulfide
ZIK02R2PSD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17961Informations de copyright
© 2022. The Author(s).
Références
Acta Biomater. 2018 Oct 15;80:288-295
pubmed: 30240956
Expert Opin Drug Saf. 2020 Mar;19(3):269-279
pubmed: 32098519
Biol Blood Marrow Transplant. 2008 Dec;14(12):1401-7
pubmed: 19041063
Theranostics. 2017 Aug 23;7(15):3667-3689
pubmed: 29109768
Drug Discov Today. 2017 Dec;22(12):1825-1834
pubmed: 28847758
ACS Appl Mater Interfaces. 2018 Apr 25;10(16):13274-13282
pubmed: 29595244
Cancer. 2012 May 1;118(9):2507-15
pubmed: 21887685
Clin Exp Med. 2015 Feb;15(1):1-18
pubmed: 25218739
Nanoscale Res Lett. 2017 Dec;12(1):328
pubmed: 28476088
Blood. 2002 May 1;99(9):3136-43
pubmed: 11964275
Clin Cancer Res. 2007 Mar 15;13(6):1762-8
pubmed: 17363530
Leukemia. 2008 Dec;22(12):2280-4
pubmed: 18528420
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21683-8
pubmed: 21118980
Mol Cancer Ther. 2016 Jul;15(7):1452-9
pubmed: 27196779
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
Leukemia. 2004 Sep;18(9):1518-21
pubmed: 15269785
Biomaterials. 2017 Jan;115:1-8
pubmed: 27871002
N Engl J Med. 1998 Nov 5;339(19):1341-8
pubmed: 9801394
Nat Commun. 2018 Jan 18;9(1):275
pubmed: 29348537
J Clin Oncol. 2006 Jun 1;24(16):2456-64
pubmed: 16651647
J Control Release. 2015 Dec 10;219:43-60
pubmed: 26407671
Oncotarget. 2016 Aug 9;7(32):52553-52574
pubmed: 27248175
J Control Release. 2019 Feb 28;296:232-240
pubmed: 30682443
J Control Release. 2014 Dec 28;196:113-21
pubmed: 25312543
Semin Hematol. 2018 Jan;55(1):19-21
pubmed: 29759148
Haematologica. 2006 Dec;91(12):1722-3
pubmed: 17145617
Int J Pharm X. 2020 May 16;2:100049
pubmed: 32490374
Toxins (Basel). 2010 Jun;2(6):1568-81
pubmed: 22069650
Cancer Res. 2008 Jan 1;68(1):190-7
pubmed: 18172311
Biomed Pharmacother. 2020 Feb;122:109712
pubmed: 31918281
Nanoscale. 2019 Mar 7;11(10):4414-4427
pubmed: 30801591
Med Oncol. 2010 Jun;27(2):203-12
pubmed: 19280372
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):292-7
pubmed: 25499624
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Adv Drug Deliv Rev. 2011 May 30;63(6):427-40
pubmed: 21223990
J Clin Oncol. 2009 Sep 20;27(27):4585-90
pubmed: 19687334
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Redox Biol. 2020 Jan;28:101310
pubmed: 31514052
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
J Nanobiotechnology. 2021 Jan 6;19(1):2
pubmed: 33407537
Trends Pharmacol Sci. 2020 Oct;41(10):730-742
pubmed: 32873407
Br J Haematol. 2007 Dec;139(5):730-43
pubmed: 18021088
Leukemia. 2017 Apr;31(4):853-860
pubmed: 27773931
J Biomed Nanotechnol. 2014 Feb;10(2):336-44
pubmed: 24738341
Leukemia. 2012 Dec;26(12):2530-7
pubmed: 22733078
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11988-93
pubmed: 23803853
Br J Haematol. 2012 Mar;156(5):679-83
pubmed: 21988294
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44
pubmed: 17601629
J Clin Oncol. 2010 Aug 20;28(24):3866-71
pubmed: 20644086
Clin Cancer Res. 2012 Nov 15;18(22):6155-68
pubmed: 22988056
Bioessays. 2016 Mar;38(3):266-75
pubmed: 26778668
J Med Chem. 2014 Jun 26;57(12):5282-92
pubmed: 24897555
Sci Rep. 2015 Dec 01;5:17579
pubmed: 26620594
Front Chem. 2022 Feb 15;10:836795
pubmed: 35242741
Drug Deliv. 2017 Nov;24(1):1482-1490
pubmed: 28958164
Nanoscale Res Lett. 2018 Nov 22;13(1):373
pubmed: 30467726
Nat Biotechnol. 2006 Oct;24(10):1211-7
pubmed: 17033654
Br J Haematol. 2017 Dec;179(5):756-771
pubmed: 29048129
ACS Nano. 2020 Apr 28;14(4):4255-4264
pubmed: 32223222
Leukemia. 2020 Jul;34(7):1971
pubmed: 31949267
Int J Cancer. 2015 Mar 1;136(5):991-1002
pubmed: 25042852
Blood. 2011 Apr 28;117(17):4409-19
pubmed: 21321360
J Control Release. 2018 Jan 28;270:158-176
pubmed: 29196043
Int J Biol Macromol. 2017 Aug;101:729-735
pubmed: 28365289
J Clin Oncol. 2001 Sep 15;19(18):3852-60
pubmed: 11559723
Biomacromolecules. 2020 Jun 8;21(6):2049-2059
pubmed: 32338875
Br J Haematol. 2004 May;125(4):470-6
pubmed: 15142117
Leukemia. 2014 Aug;28(8):1725-1735
pubmed: 24518206
Leukemia. 2012 Sep;26(9):2124-34
pubmed: 22430632
Cell Immunol. 2013 Jul-Aug;284(1-2):129-38
pubmed: 23973876
Int J Nanomedicine. 2015 Apr 30;10:3275-89
pubmed: 25995634
Nanomaterials (Basel). 2020 Dec 30;11(1):
pubmed: 33396849
Int Immunopharmacol. 2020 Jul;84:106516
pubmed: 32334387
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Int J Nanomedicine. 2014 Mar 14;9:1413-21
pubmed: 24672235
Blood. 2000 Feb 1;95(3):1056-65
pubmed: 10648422
J Vis Exp. 2018 Dec 13;(142):
pubmed: 30596388
J Clin Oncol. 2007 Sep 1;25(25):3892-901
pubmed: 17679727